{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:34:51Z","timestamp":1793896491283,"version":"4.8.0"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,4]]},"abstract":"Abstract<\/jats:title>\n \n Intensive chemotherapy (IC) is commonly used to achieve remission in patients with acute myeloid leukemia (AML). Venetoclax plus azacitidine (VEN-AZA) is FDA-approved to treat patients with AML aged\u2009\u2265\u200975\u00a0years or who are ineligible for IC. This retrospective analysis used de-identified electronic health records from the US-based Flatiron Health database from patients diagnosed 11\/21\/2018 to 10\/31\/2021 to compare treatment outcomes with VEN-AZA vs. IC. Patients were 1:1 propensity score-matched (\n \n \n $$N=276$$<\/jats:tex-math>\n \n \n N<\/mml:mi>\n =<\/mml:mo>\n 276<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n ). Assessments included rates of complete remission (CR) and hematopoietic stem cell transplant (HSCT), overall survival (OS), and relapse-free survival (RFS). CR and HSCT rates were higher with IC than with VEN-AZA (60.9% vs. 44.2% [\n P<\/jats:italic>\n \u2009=\u20090.006] and 18.1% vs. 8.0% [\n P<\/jats:italic>\n \u2009=\u20090.012], respectively). Median OS was 17.7\u00a0months in patients treated with IC and 11.3\u00a0months with VEN-AZA without censoring (\n P<\/jats:italic>\n \u2009=\u20090.278) and 13.7 vs. 10.6\u00a0months, respectively, with censoring at HSCT (\n P<\/jats:italic>\n \u2009=\u20090.584). Median RFS was 12.0\u00a0months in patients treated with IC vs. 9.5\u00a0months with VEN-AZA without censoring (\n P<\/jats:italic>\n \u2009=\u20090.431) and 6.4 vs. 7.4\u00a0months, respectively, with censoring at HSCT (\n P<\/jats:italic>\n \u2009=\u20090.444). No OS or RFS differences observed between the two arms reached statistical significance. Randomized controlled trials comparing the two approaches are warranted, as are novel approaches to reduce relapse rates following CR.\n <\/jats:p>","DOI":"10.1007\/s00277-023-05109-5","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T21:02:54Z","timestamp":1675371774000},"page":"749-754","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7017-8160","authenticated-orcid":false,"given":"Amer M.","family":"Zeidan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Pollyea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Borate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Vasconcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Potluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zephirin","family":"Kiendrebeogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lona","family":"Gaugler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Prebet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Strocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"key":"5109_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.leukres.2018.09.001","volume":"73","author":"C Talati","year":"2018","unstructured":"Talati C, Sweet K (2018) Recently approved therapies in acute myeloid leukemia: a complex treatment landscape. Leuk Res 73:58\u201366. https:\/\/doi.org\/10.1016\/j.leukres.2018.09.001","journal-title":"Leuk Res"},{"key":"5109_CR2","unstructured":"US Food & Drug Administration (FDA) website (2018) FDA approves venetoclax in combination for AML in adults. https:\/\/www.fda.gov\/drugs\/fda-approves-venetoclax-combination-aml-adults. Accessed 24 February 2022."},{"key":"5109_CR3","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH, Strickland SA, Hou J-Z et al (2019) Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study. J Clin Oncol 37:1277\u20131284. https:\/\/doi.org\/10.1200\/JCO.18.01600","journal-title":"J Clin Oncol"},{"key":"5109_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"key":"5109_CR5","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","volume":"5","author":"EM Cherry","year":"2021","unstructured":"Cherry EM, Abbott D, Amaya M et al (2021) Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv 5:5565\u20135573. https:\/\/doi.org\/10.1182\/bloodadvances.2021005538","journal-title":"Blood Adv"},{"key":"5109_CR6","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","volume":"383","author":"AH Wei","year":"2020","unstructured":"Wei AH, D\u00f6hner H, Pocock C et al (2020) Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med 383:2526\u20132537. https:\/\/doi.org\/10.1056\/NEJMoa2004444","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1007\/s00277-023-05327-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000}}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05109-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05109-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05109-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T02:02:25Z","timestamp":1687312945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05109-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":6,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["5109"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05109-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,3]]},"assertion":[{"value":"17 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00277-023-05327-x","URL":"https:\/\/doi.org\/10.1007\/s00277-023-05327-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article contains study data derived from the Flatiron Health longitudinal EHR-derived database. The databases used in the study are de-identified and compliant with the Health Insurance Portability and Accountability Act of 1996 (HIPAA). This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"AMZ has worked in a consulting\/advisory role for, received honoraria from, and provided expert testimony for AbbVie, Acceleron, Agios, Amgen, Aprea, Astellas, BeyondSpring, Boehringer Ingelheim, Bristol Myers Squibb, Cardiff Oncology, Cardinal Health, Celgene, Daiichi Sankyo, Epizyme, Geron, Gilead, Incyte, Ionis, Janssen, Jazz, Kura, Novartis, Otsuka, Pfizer, Seattle Genetics, Syndax, Taiho, Takeda, Trovagene, and TYME; has received travel\/accommodations\/expenses support from Cardiff Oncology, Novartis, and Pfizer; has provided leadership or fiduciary role in other board, society, committee or advocacy group for AbbVie, Bristol Myers Squibb, Celgene, Geron, Gilead, Kura, and Novartis; and has received research\/grant support from AbbVie, ADC Therapeutics, Amgen, Aprea, Astex, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cardiff Oncology, Celgene, Incyte, MedImmune, Novartis, Otsuka, Pfizer, Takeda, and Trovagene. DAP has received research\/grant support from AbbVie and has worked in a consulting\/advisory role for AbbVie and Genentech. UB has participated in a data safety monitoring or advisory board for AbbVie, Agios, Astellas Takeda, Blueprint, Kura, Novartis, and Servier; has received honoraria from RUNXI Foundation; and has received research support from AbbVie, Incyte, and Jazz. AV and LG are employees of Bristol Myers Squibb. RP, DR, and ZK are employed by SmartAnalyst, which received support from BMS for conducting this study. TP, CC, MS, and GB are employees of and hold stock in Bristol Myers Squibb.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}